$CDXS
CODEXIS, INC. Stock $cdxs

$cdxs Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000120037517000020 Filed on May 09, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$7.971M	$7.996M
YoY Change	-0.31%	17.62%
Cost Of Revenue	$3.002M	$2.489M
YoY Change	20.61%	70.95%
Gross Profit	$4.969M	$5.507M
YoY Change	-9.77%	3.09%
Gross Profit Margin	62.34%	68.87%
Selling, General & Admin	$6.606M	$6.802M
YoY Change	-2.88%	21.94%
% of Gross Profit	132.94%	123.52%
Research & Development	$5.839M	$5.686M
YoY Change	2.69%	7.42%
% of Gross Profit	117.51%	103.25%
Depreciation & Amortization	$326.0K	$465.0K
YoY Change	-29.89%	-16.67%
% of Gross Profit	6.56%	8.44%
Operating Expenses	$15.45M	$14.98M
YoY Change	3.14%	21.5%
Operating Profit	-$7.476M	-$6.981M
YoY Change	7.09%	26.26%
Interest Expense	$20.00K	$20.00K
YoY Change	0.0%
% of Operating Profit
Other Income/Expense, Net	$22.00K	$3.000K
YoY Change	633.33%	-88.0%
Pretax Income	-$7.436M	-$6.963M
YoY Change	6.79%	25.46%
Income Tax	$24.00K	$11.00K
% Of Pretax Income
Net Earnings	-$7.460M	-$6.974M
YoY Change	6.97%	25.39%
Net Earnings / Revenue	-93.59%	-87.22%
Basic Earnings Per Share
Diluted Earnings Per Share	-$180.8K	-$173.9K
COMMON SHARES
Basic Shares Outstanding	41.38M shares	40.47M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.90M	$22.20M
YoY Change	-37.39%	0.0%
Cash & Equivalents	$13.92M	$22.16M
Short-Term Investments
Other Short-Term Assets	$1.300M	$1.200M
YoY Change	8.33%	-7.69%
Inventory	$1.124M	$1.021M
Prepaid Expenses
Receivables	$5.381M	$4.352M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$21.74M	$28.78M
YoY Change	-24.44%	4.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.752M	$2.756M
YoY Change	-0.15%	-21.23%
Goodwill	$3.241M	$3.241M
YoY Change	0.0%	0.0%
Intangibles		$1.968M
YoY Change		-63.16%
Long-Term Investments	$1.100M	$1.500M
YoY Change	-26.67%	114.29%
Other Assets	$253.0K	$202.0K
YoY Change	25.25%	-28.87%
Total Long-Term Assets	$8.889M	$10.41M
YoY Change	-14.64%	-24.48%
TOTAL ASSETS
Total Short-Term Assets	$21.74M	$28.78M
Total Long-Term Assets	$8.889M	$10.41M
Total Assets	$30.63M	$39.19M
YoY Change	-21.84%	-5.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.493M	$2.850M
YoY Change	22.56%	46.0%
Accrued Expenses	$3.055M	$3.224M
YoY Change	-5.24%	56.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.53M	$16.48M
YoY Change	-17.94%	38.87%
LONG-TERM LIABILITIES
Long-Term Debt	$255.0K	$0.00
YoY Change
Other Long-Term Liabilities	$2.211M	$2.458M
YoY Change	-10.05%	-40.83%
Total Long-Term Liabilities	$2.466M	$2.458M
YoY Change	0.33%	-40.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.53M	$16.48M
Total Long-Term Liabilities	$2.466M	$2.458M
Total Liabilities	$18.95M	$18.94M
YoY Change	0.05%	18.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$299.5M	-$290.5M
YoY Change	3.11%	3.19%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.68M	$16.11M
YoY Change
Total Liabilities & Shareholders Equity	$30.63M	$39.19M
YoY Change	-21.84%	-5.39%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$7.460M	-$6.974M
YoY Change	6.97%	25.39%
Depreciation, Depletion And Amortization	$326.0K	$465.0K
YoY Change	-29.89%	-16.67%
Cash From Operating Activities	-$3.566M	$219.0K
YoY Change	-1728.31%	-105.69%
INVESTING ACTIVITIES
Capital Expenditures	$237.0K	$265.0K
YoY Change	-10.57%	409.62%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$30.00K
YoY Change	-100.0%	200.0%
Cash From Investing Activities	-$236.0K	-$238.0K
YoY Change	-0.84%	406.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.547M	-$1.091M
YoY Change	41.8%	151.96%
NET CHANGE
Cash From Operating Activities	-$3.566M	$219.0K
Cash From Investing Activities	-$236.0K	-$238.0K
Cash From Financing Activities	-$1.547M	-$1.091M
Net Change In Cash	-$5.349M	-$1.110M
YoY Change	381.89%	-74.35%
FREE CASH FLOW
Cash From Operating Activities	-$3.566M	$219.0K
Capital Expenditures	$237.0K	$265.0K
Free Cash Flow	-$3.803M	-$46.00K
YoY Change	8167.39%	-98.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	cdxs	Duration Company Has Been In Operation DurationCompanyHasBeenInOperation	P15Y
CY2016Q4	cdxs	Lease Incentive Obligation Noncurrent LeaseIncentiveObligationNoncurrent	885000	USD
CY2017Q1	cdxs	Lease Incentive Obligation Noncurrent LeaseIncentiveObligationNoncurrent	779000	USD
CY2017Q1	cdxs	Lessee Leasing Arrangements Capital Leases Termof Contract LesseeLeasingArrangementsCapitalLeasesTermofContract	P3Y
CY2016Q1	cdxs	Longterm Lease Incentive LongtermLeaseIncentive	106000	USD
CY2017Q1	cdxs	Longterm Lease Incentive LongtermLeaseIncentive	106000	USD
CY2016Q1	cdxs	Noncash Financing Activities Assets Acquired Under Capital Lease NoncashFinancingActivitiesAssetsAcquiredUnderCapitalLease	0	USD
CY2017Q1	cdxs	Noncash Financing Activities Assets Acquired Under Capital Lease NoncashFinancingActivitiesAssetsAcquiredUnderCapitalLease	528000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001200375
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48169923	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-91000	USD
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	CODEXIS INC
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4232000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3493000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5924000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5381000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2111000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3055000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31651000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31977000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	311164000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	311296000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	421000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	421000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	844000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6650000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7734000	shares
CY2016Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	400000	USD
CY2017Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	400000	USD
CY2016Q4	us-gaap	Assets Assets	35648000	USD
CY2017Q1	us-gaap	Assets Assets	30631000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	27227000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	21742000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12314000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	12241000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	579000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	488000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11735000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11753000	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	0	security
CY2017Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	0	security
CY2017Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	124000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	400000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	255000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	408000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	23000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	140000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	140000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	29000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	379000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	105000	USD
CY2016Q4	us-gaap	Cash Cash	8100000	USD
CY2017Q1	us-gaap	Cash Cash	2700000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23273000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22163000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19240000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13923000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1110000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5317000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12314000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12241000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41255000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41841000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41255000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41841000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7064000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7551000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2489000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3002000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1710000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1644000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1066000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2180000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	465000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	326000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4314000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5334000	USD
CY2017Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21778000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21778000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21778000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21778000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	3200000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	27000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	3241000	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Incentive From Lessor IncentiveFromLessor	1200000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6963000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7436000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-395000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-882000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2977000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-543000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-184000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1048000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	974000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1020000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	30000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	299000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1172000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	763000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-19000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-109000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	174000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	0	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-75000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	0	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	43000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	648000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	819000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	825000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	1124000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	118000	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	142000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	59000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	163000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	16549000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	18951000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35648000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30631000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-161000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	300000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12367000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13526000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	255000	USD
CY2016Q3	us-gaap	Loss Contingency Claims Dismissed Number LossContingencyClaimsDismissedNumber	5	claim
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1142000	USD
CY2017Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1051000	USD
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11200000	USD
CY2017Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11200000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1091000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1547000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-238000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	219000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3609000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-6974000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-7460000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	operating_segment
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	operating_segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	14977000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	15447000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6981000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7476000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10035000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	2000000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	531000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	712000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3280000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3185000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2327000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	200000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	259000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	253000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-90000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-91000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2231000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2211000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1098000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1636000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	265000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	237000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1238000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1314000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	27000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	99000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33806000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34729000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2155000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2752000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Transfers And Changes PropertyPlantAndEquipmentTransfersAndChanges	0	USD
CY2017Q1	us-gaap	Property Plant And Equipment Transfers And Changes PropertyPlantAndEquipmentTransfersAndChanges	0	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	10000	USD
CY2016Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	3534000	USD
CY2017Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2001000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5686000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5839000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	1624000	USD
CY2017Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	1592000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292069000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-299529000	USD
CY2016Q1	us-gaap	Revenues Revenues	7996000	USD
CY2017Q1	us-gaap	Revenues Revenues	7971000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	722000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	384000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	3740000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	5586000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6802000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6606000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1389000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1669000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.45
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4466	shares
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40582	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	19099000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	11680000	USD
CY2016Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-90000	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-91000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40072000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41250000	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, marketable securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India and Netherlands. Such deposits in those countries may be in excess of insured limits.</font></div></div>
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these notes to the consolidated financial statements, the “Company,” “we,” “us,’” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which have been continuously improved over our </font><font style="font-family:inherit;font-size:10pt;">fifteen</font><font style="font-family:inherit;font-size:10pt;"> year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many companies have historically used naturally occurring proteins to produce or enhance goods used in everyday life. Despite the growing number of commercial applications of naturally occurring proteins across many industries, the inherent limitations of naturally-occurring proteins frequently restrict their commercial use. Through the application of our proprietary CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform, we are able to engineer novel proteins to overcome these restrictions, thereby adding value or opening up new prospects for our potential clients’ products, processes or businesses. We have developed new proteins that are significantly more stable and/or active in our customers' commercial applications than proteins derived from nature.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a pioneer in the harnessing of computational technologies to drive biology advancements. Over the last fifteen years, we have made substantial investments in the development of our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development, which are all coordinated to create our novel protein innovations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform to engineer custom enzymes. Most of our custom enzymes are intended for use as biocatalysts or protein catalysts. In simple terms, our protein catalysts can accelerate and/or improve yields of chemical reactions. We use our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform to develop novel enzymes that enable industrial biocatalytic reactions and fermentations. Our technology platform has enabled commercially viable products and processes for the manufacture of pharmaceutical intermediates and active ingredients and fine chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our approach to develop commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design, using our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology. Engineered protein catalyst candidates, many thousands for each protein engineering project, are then rapidly screened and validated in high throughput under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The successful embodiment of our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for our company.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We initially commercialized our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform and products in the pharmaceuticals market, which remains our primary business focus. Our customers, which include several large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also used the technology to develop protein catalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More recently, we are also using the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business, most notably our lead program for the potential treatment of phenylketonuria ("PKU") disease in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also used our technology to develop an enzyme for customers using next generation sequencing (“NGS”) and polymerase chain reaction (“PCR/qPCR”) for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;"> molecular diagnostic and genomic research applications.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of investment securities and marketable securities, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001200375-17-000020-index-headers.html	Edgar Link	pending
0001200375-17-000020-index.html	Edgar Link	pending
0001200375-17-000020.txt	Edgar Link	pending
0001200375-17-000020-xbrl.zip	Edgar Link	pending
cdxs-20170331.xml	Edgar Link	completed
cdxs-20170331.xsd	Edgar Link	pending
cdxs-20170331_cal.xml	Edgar Link	unprocessable
cdxs-20170331_def.xml	Edgar Link	unprocessable
cdxs-20170331_lab.xml	Edgar Link	unprocessable
cdxs-20170331_pre.xml	Edgar Link	unprocessable
cdxs_20170331x10q.htm	Edgar Link	pending
cdxs_20170331xex311.htm	Edgar Link	pending
cdxs_20170331xex312.htm	Edgar Link	pending
cdxs_20170331xex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXS
CODEXIS, INC. Stock $cdxs

2017 Q1 Form 10-Q Financial Statement

#000120037517000020 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS CODEXIS, INC. Stock $cdxs

2017 Q1 Form 10-Q Financial Statement

#000120037517000020 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS
CODEXIS, INC. Stock $cdxs